Compare Dicks Sporting Goods Inc (DKS) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dicks Sporting Goods Inc vs Gilead Sciences, Inc. — how do they compare? Dicks Sporting Goods Inc trades at $135.86 (market cap $13.26B), while Gilead Sciences, Inc. trades at $147.01 (market cap $182.40B). The key difference: Gilead Sciences, Inc. is far larger — about 13.8× Dicks Sporting Goods Inc's market cap, and Dicks Sporting Goods Inc pays the higher dividend (3.71%). Which is the better fit depends on your goals — on Pluang, investors hold Dicks Sporting Goods Inc for 19 Days and Gilead Sciences, Inc. for 111 Days on average.
| DKS | GILD | |
|---|---|---|
Market Cap | $13.26B | $182.40B |
Volume | 2,292,035 | 4,469,821 |
Sector | Consumer Cyclical | Health |
52-Week High | $239.17 | $155.80 |
52-Week Low | $121.15 | $116.74 |
Typical Hold Time | 19 Days | 111 Days |
Enterprise Value | $20.31B | $205.46B |
Dividend Yield | 3.71% | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DICK'S Sporting Goods (DKS) trades at $131.18, down 2.74% on the day, amid a bearish technical signal and ongoing securities class action news. The stock shows mixed fundamentals with a trailing P/E of 14.86 and P/S of 0.57, while recent earnings beat estimates in two of the last three quarters. Revenue grew to $13.44B in 2025, though net income margin compressed to 3.97% in 2026 trends. Analyst consensus remains positive with a $153.30 price target and 57% buy ratings, but legal overhangs and a negative cash flow trend present headwinds.
The investment case balances attractive valuation multiples against significant litigation risks and weakening profitability. Upside exists if the company navigates legal challenges and stabilizes margins, but the bearish technical setup and negative investor sentiment suggest caution. The stock's near-term direction will likely hinge on Q3 2026 earnings results and developments in the class action lawsuit.
Gilead Sciences (GILD) trades at $146.85, up 1.82% with bullish technical signals and strong analyst support. Recent earnings beat expectations in three consecutive quarters, though Q2 showed a significant loss. The company maintains robust operating cash flow of $10.02B (2025) and expanded HIV prevention access through a major PAHO partnership. Valuation metrics show a P/E of 17.84 and P/S of 6.02, with revenue growth from $29.44B (2025) to projected $30.5B (2026).
Outlook remains positive with 65% analyst buy ratings and $151.57 consensus target, though risks include negative net income margin (-10.64%) and high debt levels. The stock offers dividend income ($0.82 upcoming) and pipeline catalysts in oncology/HIV, but investors should monitor earnings volatility and competitive pressures in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dicks Sporting Goods Inc
Dick's Sporting Goods is a leading omni-channel sporting goods retailer in the US It offers an extensive assortment of authentic sports equipment, apparel, footwear, and accessories through its stores and digital platforms.
Read more on DKS →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
